Health & Pharma regulatory framework to make a topical discussion during the X Saint Petersburg International Legal Forum in May, 2020.
The estimated volume of medicines consumer market in Russia reached USD 7.5bn in 2019. Big Pharma still tops the sales, but national manufacturers get stronger. Still, the market has the capacity for many new players to come, and firm grasp of the regulatory environment – the one in place, and the one-to-be, – is the key criteria for success.
Join the prominent business executives, legal professionals and government officials in Saint Petersburg, Russia, on May 19-23, 2020, to get the understanding of the current opportunities and issues for an international health & pharmaceutical industry provider in terms of law and regulatory framework. This is when the X Saint Petersburg International Legal Forum takes place.
For five days each year, Saint Petersburg becomes a legal capital of the world: thousands of professionals from all continents come here to share experience and discuss the most topical and pressing legal issues. The Forum is an effective platform for dialogue of the state, business and legal community. There are no “red zones” here; each participant is an equal among equals.
- talk to the leading experts and regulators and get insider knowledge from the decision makers.
- negotiate contracts, meet future partners and clients, and get the things done while otherwise it would have taken weeks.
- see the city of Saint Petersburg during White Nights, the most admirable season of the year and enjoy an outstanding social events programme.
The SPBILF agenda features a set of discussion panels devoted to pharmaceutical sector regulatory and legislative issues. Last year, the topics included:
- The main directions of state policy in the Health & Pharma industry. Pharma Strategy 2030 and industry support measures.
- Parallel import: Pros and contras.
- Compulsory licensing: today and tomorrow.
- E-commerce in pharma and medical service: future is now.
- Public procurement of medicines: intersubstitutability and GMP certificates.
Hands-on reports on the current industry regulatory environment and prospective developments were delivered by, among others:
- Assistant Director General, World Intellectual Property Organization.
- Director General, Russian Federal Service for Intellectual Property.
- President, Eurasian Patent Office.
- First Deputy Minister of Industry and Trade of Russia.
- Director of the Department of Drug Supply and Regulation of Medical Products, Russian Ministry of Health.
- Head of the Department for Control over Social Sphere and Trade of the Russian Federal Antimonopoly Service.
- CEOs of national sector leaders such as ChemRar Pharma, Biocad and Sintez.
- Key legal executives of Novartis, Johnson & Johnson, STADA, Servier and Geropharm.
Health & Pharma focused discussion panels are conveniently held with one day, and the industry delegates are entitled to a special participation fee – One-Day Delegate Pass.
Learn more about the event and register online at www.spblegalforum.com.